Stellar Biotechnologies focuses on stakeholder-responsive principles of corporate governance. We believe these ideas are keys to the success of our company and the trust of our stockholders, employees, customers, suppliers and co-research and development partners. Please report complaints and concerns about our company to any of our members of the Board of Directors.

Please make requests for the company's Articles of Incorporation, By-Laws or Audit Committee documents through the web-site "Contact" page. Such requests will be responded to with the documentation via email.

Stellar Biotechnologies, Inc. (all $ amounts in CDN$)

Symbol:	(SBOTF on OTCQB; KLH on TSX-V;
Public Filings on www.Sedar.com and EDGAR
CUSIP #:	85855A104
ISIN #:	CA85855A1049
Transfer Agent:
Computershare Trust Company of Canada Vancouver, BC, CANADA
Fiscal Year End:	August 31

 

Canadian Regulatory Address: Stellar Biotechnologies, Inc. 401 – 1231 Barclay Street Vancouver, BC  V6E 1H5 CANADA Tel:  (604) 200-7855 Toll Free:  (888) 909-4767

U.S. Corporate Address: Stellar Biotechnologies, Inc. 332 E. Scott Street Port Hueneme, CA 93041 USA Phone: (805) 488-2800 Fax: (805) 488-2889 www.stellarbiotechnologies.com

Capital Structure:

Shares Outstanding:
app. 54M (As of April 15, 2013)

Options Outstanding:
app. 6M priced from CDN $0.25 - $1.15 (As of April 15, 2013)

Warrants Outstanding: 
app. 11M priced from CDN $0.40 - $0.75 (As of April 15, 2013)

Performance Shares to certain key employees and advisors: app. 6M
 

Banking:

Canada: Royal Bank of Canada
USA: Wells Fargo Bank
 

Auditor:

D & H Group LLP
Vancouver, BC, CANADA
 

Corporate & Securities Attorneys:

McMillan LLP
Vancouver, BC, CANADA

Stradling, Yocca, Carlson & Rauth
Santa Barbara, CA, USA

Investor Contact:
dbrookstein@StellarBiotech.com